No Data
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
Astria Therapeutics' Potential Hereditary Angioedema Treatment Gets FDA Orphan Drug Designation
Express News | Astria Therapeutics: To Share Additional Results From Alpha-Star Trial in Q4 & to Progress Navenibart Into Phase 3 Trial Initiating in Q1 2025
Express News | Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (Star-0215) for the Treatment of Hereditary Angioedema
No Data
No Data